AP
LRMR icon

Aspect Partners’s Larimar Therapeutics LRMR Stock Holding History

Aspect Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,000
Closed -$6.55K – 614
2024
Q3 		$6.55K Hold
1,000
– – ﹤0.01% 324
2024
Q2 		$7.25K Hold
1,000
– – ﹤0.01% 301
2024
Q1 		$7.59K Buy
+1,000
New +$7.79K 0.01% 301

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Aspect Partners's LRMR Position: Q4 2024 in Review

Aspect Partners sold out of Larimar Therapeutics (LRMR) in Q4 2024, closing a stake of 1,000 shares — an estimated $6.55K sold.

Aspect Partners first reported a position in LRMR in Q1 2024 and held it in 3 quarters. The position peaked at $7.59K in Q1 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q4 2024.

  • Aspect Partners reported no remaining Larimar Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Aspect Partners sold 1,000 Larimar Therapeutics shares in Q4 2024, an estimated $6.55K.
  • Aspect Partners first reported a position in Larimar Therapeutics in Q1 2024 and held it in 3 quarters.
  • Aspect Partners's Larimar Therapeutics position peaked at $7.59K in Q1 2024.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2024.

Based on Aspect Partners's 13F filing for Q4 2024, filed 3 Feb 2025.